2009
DOI: 10.3892/ijo_00000342
|View full text |Cite
|
Sign up to set email alerts
|

Halofuginone mediated protection against radiation-induced leg contracture

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2015
2015
2023
2023

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 7 publications
(2 citation statements)
references
References 21 publications
0
2
0
Order By: Relevance
“…This leads to accumulation of uncharged proline tRNAs and subsequent GCN2 activation. Halofuginone has been shown to be protective in models of etiologically-diverse diseases including ischemic disorders, cardiovascular disease, and many cancers (Ishii et al ., 2009; Juarez et al ., 2012; Pines & Spector, 2015). However, apart from ISR activation, halofuginone can also promote protection through other mechanisms including inhibition of TGF β signaling (Pines & Spector, 2015).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…This leads to accumulation of uncharged proline tRNAs and subsequent GCN2 activation. Halofuginone has been shown to be protective in models of etiologically-diverse diseases including ischemic disorders, cardiovascular disease, and many cancers (Ishii et al ., 2009; Juarez et al ., 2012; Pines & Spector, 2015). However, apart from ISR activation, halofuginone can also promote protection through other mechanisms including inhibition of TGF β signaling (Pines & Spector, 2015).…”
Section: Discussionmentioning
confidence: 99%
“…Tyrosine kinase inhibitors such as erlotinib and sunitinib were also shown to activate GCN2 through a mechanism potentially involving direct binding to this ISR kinase (Tang et al , 2022). Like PERK activators, these other ISR kinase activators, most notably BtdCPU and halofuginone, have been shown to be protective in cellular and in vivo models of numerous disorders, further highlighting the potential for pharmacologic ISR activation in disease (Chen et al ., 2011; Ishii et al , 2009; Juarez et al , 2012; Keller et al ., 2012; Tian et al , 2021). However, the capacity for these compounds to promote adaptive mitochondrial remodeling in wild-type cells or cells deficient in PERK activity is currently unknown.…”
Section: Introductionmentioning
confidence: 99%